TB-500 FAQ: Common Questions on Mechanism, Safety, and Research | MD/TB-500
What is TB-500?
TB-500 is a synthetic heptapeptide — seven amino acids, sequence Ac-LKKTETQ — corresponding to positions 17-23 of endogenous thymosin beta-4 (a 43-amino-acid actin-sequestering protein). Molecular weight: 801.9 Da. The fragment retains the actin-binding domain of the parent protein and has been studied in rodent and equine tissue-repair models. Not FDA-approved for any human indication [1].
What does TB-500 do?
In preclinical studies TB-500 promotes cell migration and differentiation by binding G-actin monomers, preventing premature filament polymerization. Downstream effects include ILK/Akt survival signaling, NF-kB-mediated inflammatory cytokine suppression, and VEGF-driven angiogenesis — four coordinated pathways that converge on tissue repair and inflammation resolution [1] [2].
What is the difference between TB-500 and thymosin beta-4?
Thymosin beta-4 is a 43-amino-acid endogenous protein (the primary G-actin sequestering molecule in mammalian cells). TB-500 is a synthetic seven-amino-acid fragment (Ac-LKKTETQ, residues 17-23) that retains the actin-binding domain and much of the bioactivity of the parent protein in preclinical models. The two differ in size, pharmacokinetics, and extent of human study [1] [2].
What is TB-500 used for?
Research applications documented in the preclinical literature include tendon and ligament repair, dermal wound healing, corneal wound repair, cardiac ischemia protection, post-extraction bone healing, and hair follicle activation. All are studied primarily in rodent models; no human clinical trial of the TB-500 heptapeptide has been published [1] [3] [4] [5] [11].
What are the benefits of TB-500 peptide?
Preclinical data document: accelerated wound closure and reduced inflammatory cell infiltration [13], improved collagen fiber organization and ligament mechanical strength [3], reduced myofibroblast accumulation and minimal scarring in incisional wounds [4], cardiac infarct size reduction [5], and hair follicle anagen-phase acceleration in murine models [11]. No controlled human trial has confirmed these outcomes for the heptapeptide.
What are the most common side effects of TB-500?
Animal studies and anecdotal equine reports note transient fatigue, injection-site irritation, and mild nausea. Phase 1 human studies of full-length thymosin beta-4 at IV doses of 42-1260 mg reported no dose-limiting toxicity [9] [12]. No human safety profile for the TB-500 heptapeptide specifically has been published.
Can TB-500 cause cancer or tumor growth?
In a mouse melanoma model, adenoviral overexpression of thymosin beta-4 produced tumors of 21.7 mm versus 13.3 mm in controls and lung metastasis counts of 46.7 versus 10.9 — the proposed mechanism is VEGF-driven angiogenesis and migration [17]. No direct tumor-promotion has been observed in standard preclinical toxicity protocols at research doses. The question remains unresolved in long-duration studies and in subjects with pre-existing malignancy.
Is TB-500 safe?
Short-term safety data from full-length thymosin beta-4 Phase 1 human studies are favorable: no dose-limiting toxicity at IV doses of 42-1260 mg [9], no serious adverse events in a 84-volunteer Phase 1 study of recombinant Tβ4 [12]. No validated human safety data for the TB-500 heptapeptide fragment exist. Anti-doping bodies (WADA, BSCG) prohibit TB-500 in competitive sport.
Is it safe to take a TB-500 peptide?
No human safety trial of the TB-500 heptapeptide specifically has been published. Safety inference is drawn from full-length thymosin beta-4 studies, which documented favorable short-term profiles in Phase 1 human trials [9] [12]. Long-term and heptapeptide-specific human safety data are absent. The tumor-promotion concern from the melanoma mouse model [17] is a theoretical consideration for subjects with active malignancy.
What are the implications of anti-doping regulations for athletes considering TB-500?
TB-500 is explicitly prohibited by WADA under S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors) as a Non-Specified Substance banned both in and out of competition. WADA-accredited labs detect TB-500 via LC-MS/MS at 0.02 ng/mL in equine plasma [8]. Athletes testing positive face sanctions; the Canadian Centre for Ethics in Sport issued a four-year ineligibility for a non-analytical TB-500 positive.
Does TB-500 need to be injected near the injury?
Animal studies show systemic distribution regardless of injection site — subcutaneous administration at distal sites still reaches target tissues in rodent models [1]. Localized injection is therefore not required for bioavailability based on preclinical data. Whether this translates to human tissue distribution has not been validated in any published human study.
How long does TB-500 take to work?
In rodent wound-healing models, measurable tissue-repair markers appear within 48-72 hours — a 2024 rat study showed enhanced angiogenesis detectable at day 3 [13]. Equine literature references loading phases of 4-6 weeks for observed clinical improvement. Human onset data for the heptapeptide have not been characterized in any published study.
How long does TB-500 stay in your system?
No validated pharmacokinetic data for the TB-500 heptapeptide in humans have been published. Preclinical principles suggest rapid plasma clearance (sub-hour to a few hours) with tissue-level bioactivity potentially persisting beyond plasma clearance. WADA-accredited labs detect Ac-LKKTETQ and metabolites in equine plasma and urine post-administration [8]. Human detection windows are not characterized in published literature.
How long should a standard TB-500 cycle last?
No published human clinical trial has established a cycle duration for TB-500. Equine literature references loading phases of 4-6 weeks; this reflects veterinary/sport observations, not validated therapeutic protocols. The Phase 1 human studies of full-length thymosin beta-4 used 10-14 day multi-dose observation periods as pharmacokinetic windows [9] [12], not as therapeutic cycle recommendations.
What is the standard reconstitution protocol for TB-500?
Laboratory and equine literature describes reconstitution of lyophilized TB-500 with bacteriostatic water (0.9% benzyl alcohol). Commercial equine vial concentrations range from 2-5 mg. Storage: lyophilized at -20°C; reconstituted solution at 2-8°C. These are laboratory research-setting practices, not approved pharmaceutical preparation instructions.
What injuries respond best to TB-500?
Preclinical models with the most robust data include: medial collateral ligament transection in rats [3], incisional and burn wound healing in rats and mice [4] [10] [13], corneal scrape wound and alkali burn models [16], and cardiac ischemia models in mice [5]. Musculoskeletal soft tissue (tendon, ligament) and corneal wound healing have the broadest preclinical record.
Does TB-500 help with hair loss?
Thymosin beta-4 activates follicle stem cells and stimulates hair follicle development in murine models. Transgenic overexpressors showed faster hair regrowth after depilation; knockouts showed slower regrowth [11] [11]. Overexpressors had elevated VEGF, MMP-2, and activated P38/ERK/AKT signaling [11]. No human clinical trial of TB-500 for hair growth has been published.
Does TB-500 increase hair growth?
In transgenic and knockout murine models, thymosin beta-4 expression level directly correlated with hair regrowth speed after depilation [11] [11]. Elevated follicle clustering, higher hair shaft numbers, and P38/ERK/AKT pathway activation were observed in overexpressors. This is a murine finding for the full-length parent protein; no human hair growth data exist for TB-500.
Is TB-500 good for your heart?
Thymosin beta-4 reduced infarct size and improved cardiac function in mouse coronary artery ligation models via ILK-Akt pathway activation [5]. A 2021 scaffold-delivery study demonstrated sustained Tβ4 release activating epicardial progenitor cells and reducing fibrotic scar in infarcted rat myocardium [15]. All cardiac outcomes are from animal models with the full-length parent protein.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid gastric-derived peptide acting via growth hormone receptor signaling and NO pathway activation; TB-500 is a 7-amino-acid thymosin beta-4 fragment acting via G-actin dynamics, ILK/PINCH/Akt signaling, and NF-kB inhibition. Both show tissue-repair properties in rodent models but through non-overlapping upstream mechanisms. See the TB-500 vs BPC-157 comparison on the research page.
Can you use TB-500 with BPC-157?
The combination (colloquially called the 'Wolverine Stack') is a subject of mechanistic research interest. BPC-157 acts via growth hormone receptor and NO pathways; TB-500 acts via actin dynamics and ILK/PINCH/Akt. The two compounds operate through non-overlapping pathways, providing a mechanistic rationale for co-investigation. Published peer-reviewed evidence on co-administration in a single study is limited.
Has anyone studied BPC-157 and TB-500 together?
No published peer-reviewed study has evaluated BPC-157 and TB-500 (Ac-LKKTETQ) in combination in a single controlled experiment. The mechanistic rationale for co-investigation is documented in individual compound studies — complementary non-overlapping pathways — but direct co-administration data have not been published as of 2026.
Is TB-500 legal?
TB-500 is not FDA-approved for any human indication. It is prohibited in competitive sport by WADA under S0 and S2 of the annual Prohibited List. In the US it exists in a regulatory gray area as an unapproved research chemical. Regulatory status varies by jurisdiction — some countries regulate it as an unapproved pharmaceutical, others as an unregulated research compound [8].
Can TB-500 be detected in drug tests?
WADA-accredited labs detect TB-500 (Ac-LKKTETQ) via LC-MS/MS in equine urine and plasma at detection limits of 0.01 ng/mL and 0.02 ng/mL respectively [8]. This was the first confirmed detection of TB-500 and metabolites in post-administration equine samples. Human detection windows in urine are not fully characterized in published literature.
Are there specific contraindications to the use of TB-500?
Theoretical contraindications from mechanism-based reasoning and review literature: active malignancy (VEGF-driven angiogenic mechanism, melanoma mouse model finding [17]), pregnancy (no safety data), autoimmune conditions (immune-modulating properties), pre-existing thyroid disorders (flagged in review literature). No evidence-based contraindication list can be established without human safety trial data.
Can TB-500 peptide cause allergic reactions?
Hypersensitivity reactions are theoretically possible with any exogenous peptide. Anecdotal reports describe local injection-site reactions (erythema, swelling) consistent with non-specific peptide injection responses. Systematic allergy data from controlled TB-500 studies are absent. Phase 1 human studies of full-length thymosin beta-4 [9] [12] and Phase 2 wound studies [6] [7] did not document systemic hypersensitivity or anaphylaxis.
What are the key benefits of TB-500 for joint pain?
Preclinical models show TB-500's parent protein reduces inflammatory cytokines and promotes connective tissue repair: MCL transection in rats showed improved collagen fiber organization and mechanical strength [3]; NF-kB-mediated cytokine suppression was documented in cell studies [14]. No controlled joint-pain studies in humans have been published for TB-500 specifically.
Does TB-500 have any hormonal side effects?
TB-500 acts via actin-cytoskeletal and ILK signaling, not on hormonal axes. Endocrine disruption has not been observed in standard preclinical toxicity protocols. TB-500 is not a growth hormone secretagogue and does not directly affect the HPG or adrenal axes based on any published mechanism. Phase 1 human thymosin beta-4 studies did not report endocrine adverse events [9] [12].
What is the current scientific evidence supporting the use of TB-500?
The evidence base: primarily in vitro mechanistic studies and rodent models, with equine doping data and limited human evidence from full-length thymosin beta-4 (Phase 1 safety, Phase 2 topical wound healing). No randomized controlled human trial of the TB-500 heptapeptide specifically has been published as of 2026. The mechanistic framework is well-characterized; clinical translation remains an open research question [1] [9] [12].
How do TB-500 and BPC-157 compare to established regenerative medicine therapies?
PRP and stem cell therapies have larger controlled human trial datasets. Thymosin beta-4 has Phase 1 human safety data [9] [12] and Phase 2 topical wound healing data [6] [7]; the heptapeptide TB-500 has no human trial. The molecular mechanism is well-characterized — actin dynamics and ILK signaling are established pathways — but clinical evidence remains preclinical for the fragment.